



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/056,347	01/25/2002	Ronald M. Burch	200.1079CON2	8306
23280	7590	08/26/2004		
DAVIDSON, DAVIDSON & KAPPEL, LLC 485 SEVENTH AVENUE, 14TH FLOOR NEW YORK, NY 10018			EXAMINER CELSA, BENNETT M	
			ART UNIT	PAPER NUMBER
			1639	

DATE MAILED: 08/26/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/056,347

Applicant(s)

BURCH ET AL.

Examiner

Bennett Celsa

Art Unit

1639

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 38-44, 46 and 47 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 38-44, 46 and 47 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>11/29/02</u> . | 6) <input type="checkbox"/> Other: ____. |

DETAILED ACTION

Status of the Claims

Claims 38-44 and 46-47 are currently pending and under consideration..

Election/Restriction

1. Applicant's election without traverse of Group II (claims 38-44 and 46-47; use in methods of oxycodone and meloxicam) in the correspondence dated 6/14/04 is acknowledged. Applicant's response to non-compliant amendment dated 7/28/04 is acknowledged.

Priority

Applicant should update the cross-reference to parent application which has subsequently issued as a patent.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

Art Unit: 1639

consider the applicability of 35 U.S.C. 103[©] and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 38-44 and 46-47 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baker et al. US Pat. No. 4,569,937 (2/86), Engelhardt et al. Inflamm. Res. 44:423-433 (1995), Engelhart Brit. J. Rheumatol. 1996:35(suppl.1): 4-12 and Distel et al. Brit. J. Rheumatol. 1996:35(suppl.1):68-77.

Baker et al. teach pharmaceutical compositions for relieving pain in humans or mammals (e.g. mice, rats etc.) comprising a combination of :

a. a narcotic analgesic (preferably oxycodone: see formulations col. 4-8; mice data in col. 8-10; patent claims), or a pharmaceutically acceptable salt thereof; and

b. ibuprofen (a non-steroidal anti-inflammatory drug or NSAID: see col. 1-2), or a pharmaceutically acceptable suitable salt thereof,

in a weight ratio of about 1:800 (e.g. .001:1) to 1:1 (compare to present claim 47: See col. 2)

with oxycodone amounts of about 5 mgs-600mgs (compare to present claim 46).

The Baker reference teaches oral administration (e.g. see present claim 39), which can be coadministered in a "single dosage form" (e.g. see col. 3-8: and present claim 40) or sequentially administered (e.g. as in present claim 42; see i.e. col. 8-9 ; "... mice are dosed sequentially..."). The Baker et al. reference teach that dose ratios can be adjusted and that the analgesic activity of the combined oxycodone and ibuprofen activity is "unexpectedly enhanced" or synergistic "i.e. the resulting activity is greater than the activity expected from the sum of the activities of the individual components",

thereby permitting "reduced dosages of narcotic analgesics" (e.g. oxycodone) AND which diminishes adverse side effects (e.g. addiction) and toxicity which would result from the otherwise required amounts of the individual drug components" resulting from high dosages of oxycodone or NSAID's such as ibuprofen. See e.g. col. 1-2; col. 3, lines 19-32 (e.g. compare to present 43 and 44 "reduced" active ingredients).

Accordingly, Baker would teach the use of therapeutic and subtherapeutic amounts of oxycodone and/or ibuprofen in view of the synergistic nature of the combinations and the desire to reduce the toxicity and/or side-effects of both agents; and as required by the doctor for his/her particular patient., including dosage optimization e.g. dosage overlapping of active ingredients. See e.g. col. 3 where dosage is modified to suit the particular patient.

The Baker analgesic composition differs from that presently claimed in that it fails to teach the substitution of meloxicam for ibuprofen, or alternatively, the further incorporation of (e.g. encompassed by "consisting essentially of") meloxicam into the Baker compositions.

Engelhardt et al. teach that meloxicam, as compared to other NSAID's (e.g. indomethacin, naproxen etc.) in animal models (e.g. rat):

- a. was more efficacious when orally administered in a single dose (e.g. anti-exudative effect; more potent ; more prolonged with a better therapeutic range);
- b. had good analgesic effect on inflammatory pain; and
- c. had fewer side-effects e.g. inhibited both bradykinin-induced bronchospasm; greater GI tolerance. See e.g. abstract and animal data.

Similarly, Engelhardt teaches that compared to other NSAID's meloxicam has an improved safety profile and good tolerability with high and long-lasting anti-inflammatory and analgesic effects in an animal model (e.g. rats). See abstract and animal data.

Further, the Distel et al. reference teaches that meloxicam is a "preferred" NSAID/COX-2 inhibitor (as compared to other NSAID's e.g. piroxicam/naproxen) which in clinical trials is efficacious in the treatment of arthritic pain patients (e.g. osteo/rheumatoid arthritis) but has shown to be more safe, with reduced side-effects (e.g. dyspepsia, ulcers, reduced hemoglobin, gastritis etc.). See Distel et al. Abstract and disclosed studies.

Accordingly, one of ordinary skill in the art would have been motivated to substitute meloxicam (a NSAID) for ibuprofen (a different NSAID) in the Baker reference compositions in light of the Engelhardt et al., Engelhardt and Distel et al. reference teachings that meloxicam is at least equally efficacious, but is safer with less side effects (e.g. as compared to othe NSAID's i.e. ibuprofen).

Alternatively, one of ordinary skill in the art would have been motivated to incorporate meloxicam, with its potent analgesia and reduced side-effect, into the Baker ibuprofen/oxycodone compositions in order to reduce the amounts (e.g. therapeutic/subtherapeutic) of ibuprofen/oxycodone in order to avoid the side effects (e.g addiction) or toxicity resulting from ibuprofen/oxycodone. Additionally, it is noted that the instant situation is amenable to the type of analysis set forth in *In re Kerkhoven*, 205 USPQ 1069 (CCPA 1980) wherein the court held that it is *prima facie*

obvious to combine two (or more) compositions each of which is taught by the prior art to be useful for the same purpose

Thus, it would have been prima facie obvious to one of ordinary skill in the art at the time of applicant's invention to modify the Baker reference analgesic composition by substituting the NSAID meloxicam (for the NSAID ibuprofen) or supplementing Baker's composition with meloxicam in light of the benefits of meloxicam (increased safety/decreased side effect as compared to ibuprofen) as taught by the Engelhardt et al., Engelhardt and Distel et al. references.

4. Claims 38-44 and 46-47 are rejected under 35 U.S.C. 103(a) as being unpatentable over as the Baker et al. '937, Engelhardt et al., Engelhardt and Distel et al. References applied to claims 38-44 and 46-47 above, and further in view of Mayer et al. US Pat. No. 5834,479 (11/98).

The teaching of the Baker, Engelhardt et al., Engelhardt and Distel et al. References recited above is hereby incorporated by reference in its entirety.

To the extent that the Baker, Engelhardt et al., Engelhardt and Distel et al. references fail to teach the administration of the analgesia active agent (e.g. meloxicam) "before, ... with, or after" administration of the oxycodone" (particularly before/after) (e.g. see present claim 42) the Mayer et al. reference is cited.

The Mayer et al. reference teaches that analgesia effectiveness of an analgesia active agent (e.g. a NSAID, such as ibuprofen see i.e. table in col. 7) can be "significantly enhanced" by administering (e.g. oral administration) the active agent

Art Unit: 1639

“prior to, with or following the administration of an analgesia enhancer” (e.g. a nontoxic NMDA receptor blocker and/or a nontoxic substance that blocks at least one major intracellular consequence of NMDA receptor activation) such as “dextromethorphan”, which is the D-isomer of codeine . See e.g. col. 1; patent claims.

Accordingly, the Mayer et al. reference provides motivation to one of ordinary skill in the art to not only co- administer different analgesic agents to achieve enhanced analgesia, but to also administer the NSAID prior or subsequent to the second analgesic agent i.e. an analgesia enhancer, which includes codeine or its derivatives (e.g. dextromethorphan, dextrophan, oxycodone etc.) .

Thus, it would have been prima facie obvious to one of ordinary skill in the art at the time of applicant's invention to modify the Baker, Engelhardt et al., Engelhardt and Distel et al. reference teachings by administering one of the analgesic active agents (e.g. meloxicam) “before, ... with, or after” administration of the second analgesic agent (e.g. oxycodone) in order to obtain significantly enhanced analgesia.

Cumulative Prior Art:

1. Wojtulewski et al., British J. Rheumatology 1996 : 35 (Suppl.1) : 22-28.


Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bennett Celsa whose telephone number is 571-272-0807. The examiner can normally be reached on 8-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571-273-0811. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bennett Celsa
Primary Examiner
Art Unit 1639



BC
August 12, 2004